Medical debulking with BRAF/MEK inhibitors in aggressive BRAF-mutant craniopharyngioma

Anna Luisa Di Stefano (1, 2) , David Guyon (1) , Karine Sejean (1) , Loic Feuvret (3, 4, 5) , Chiara Villa (1) , Giulia Berzero (6) , Virginie Desforges Bullet (7) , Emmanuel Halimi (1) , Anne Boulin (1) , Bertrand Baussart (1) , Stephan Gaillard (1)

1 Hôpital Foch [Suresnes]
2 ICM - Institut du Cerveau = Paris Brain Institute
3 CHU Pitié-Salpêtrière [AP-HP]
4 Institut Curie [Paris]
5 Centre de Protonthérapie d'Orsay
6 UNIPV - Università degli Studi di Pavia = University of Pavia
7 CHV - Centre Hospitalier de Versailles André Mignot

Mots clés: kinase kinase inhibitors; Molecular Tumor; anti-BRAF; anti-MEK; BRAF V600E mutation; papillary craniopharyngioma; target therapy; debulking; craniopharyngioma; braf gene; mitogen-activated; protein kinase inhibitors; braf v600e mutation; mitogen-activated protein

Domaines: Médecine humaine et pathologie

Anna Luisa Di Stefano, David Guyon, Karine Sejean, Loic Feuvret, Chiara Villa, et al.. Medical debulking with BRAF/MEK inhibitors in aggressive BRAF-mutant craniopharyngioma. Neuro-Oncology Advances, 2020, 2 (1), ⟨10.1093/noajnl/vdaa141⟩. ⟨hal-03033648⟩